Literature DB >> 6331553

Serum cold agglutinin and IgM levels in breast carcinoma.

V E Dube, M Haid, J S Chmiel, B Anderson.   

Abstract

Breast carcinoma (BCa) cells produce I antigen or I antigen-like substances that may influence serum anti-I. We determined cold hemagglutinins in 170 BCa patients, 97 women with benign breast disease, and 37 female controls of comparable ages to the patients. The results were expressed as an anti-I score. Serum IgM was measured by radial immunodiffusion. The data for the BCa patients were analyzed by pathologic stage (PS) and histologic category. The anti-I score for PS III (28.1 +/- 13.0; mean +/- S.D.) was higher (p less than 0.02), and that for PS IV (11.4 +/- 7.4) lower (p less than 0.02) than the control value (17.7 +/- 10.2). IgM concentrations of the BCa patients as a group or by PS were similar to those of the controls. The mean anti-I scores were higher in mucinous (31.1 +/- 14.9, p less than 0.001) and apocrine BCa (28.6 +/- 16.2, p less than 0.02) compared to the control value. IgM concentrations were elevated in mucinous (218.1 +/- 85.8 mg/dl, p less than 0.01) and apocrine BCa (241.9 +/- 99.0, p less than 0.005) compared to the control value (157.1 +/- 66.9). The results suggest an association of anti-I scores and PS of BCa and suggest an antigenic difference of mucinous and apocrine from infiltrative ductal BCa.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6331553     DOI: 10.1007/bf01806392

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  8 in total

1.  Serum immunoglobulin levels in patients with breast cancer.

Authors:  M M Roberts; E M Bathgate; A Stevenson
Journal:  Cancer       Date:  1975-07       Impact factor: 6.860

Review 2.  The blood group Ii system: a carbohydrate antigen system defined by naturally monoclonal or oligoclonal autoantibodies of man.

Authors:  T Feizi
Journal:  Immunol Commun       Date:  1981

3.  Philip Levine Award Lecture. Contributions of quantitative immunochemistry to knowledge of blood group A, B, H, Le, I and i antigens.

Authors:  E A Kabat
Journal:  Am J Clin Pathol       Date:  1982-09       Impact factor: 2.493

Review 4.  Blood group ABH and Ii antigens of human erythrocytes: chemistry, polymorphism, and their developmental change.

Authors:  S Hakomori
Journal:  Semin Hematol       Date:  1981-01       Impact factor: 3.851

5.  Serum concentrations of G, A, and M immunoglobulins in patients with carcinoma, melanoma, and sarcoma.

Authors:  N R Hughes
Journal:  J Natl Cancer Inst       Date:  1971-05       Impact factor: 13.506

6.  Blood-group precursors and cancer-related antigens.

Authors:  T Feizi; C Turberville; J H Westwood
Journal:  Lancet       Date:  1975-08-30       Impact factor: 79.321

7.  Red blood cell cold agglutinins and B lymphocyte cytotoxins in breast cancer sera.

Authors:  V Dube; Y Iwaki; B Anderson; P Terasaki
Journal:  Vox Sang       Date:  1982       Impact factor: 2.144

8.  Status of blood group carbohydrate chains in ontogenesis and in oncogenesis.

Authors:  K Watanabe; S I Hakomori
Journal:  J Exp Med       Date:  1976-09-01       Impact factor: 14.307

  8 in total
  3 in total

1.  Engagement of I-branching {beta}-1, 6-N-acetylglucosaminyltransferase 2 in breast cancer metastasis and TGF-{beta} signaling.

Authors:  Haijun Zhang; Fanyan Meng; Sherwin Wu; Bas Kreike; Seema Sethi; Wei Chen; Fred R Miller; Guojun Wu
Journal:  Cancer Res       Date:  2011-07-12       Impact factor: 12.701

Review 2.  The structural relationship of blood group-related oligosaccharides in human carcinoma to biological function: a perspective.

Authors:  V E Dube
Journal:  Cancer Metastasis Rev       Date:  1987       Impact factor: 9.264

Review 3.  Natural and adaptive IgM antibodies in the recognition of tumor-associated antigens of breast cancer (Review).

Authors:  Mariana Díaz-Zaragoza; Ricardo Hernández-Ávila; Rubí Viedma-Rodríguez; Diego Arenas-Aranda; Pedro Ostoa-Saloma
Journal:  Oncol Rep       Date:  2015-06-30       Impact factor: 3.906

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.